Aratana

PETX NASDAQ
4.760
-0.040
-0.83%
After Hours: 4.760 0 0.00% 17:23 05/24 EDT
Open
4.820
Prev Close
4.800
High
4.820
Low
4.710
Volume
231.49K
Avg Vol (3M)
915.49K
52 Week High
7.16
52 Week Low
3.300
% Turnover
0.47%
Market Cap
233.09M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Aratana PETX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
MORE >

Recently

Name
Price
%Change